B, Angermeyer MC, Leese M, Thornicroft G, Schene A, Kikkert M, Burti L, Tansella M, Becker T: Course of adherence to medication and high-quality of life in individuals with schizophrenia. Psychiatry Res 2009, 165:224?three. 16. Falkai P: Limitations of present therapies: why do individuals switch therapies? Eur Neuropsychopharmacol 2008, three:S135?. 17. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV: Prevalence of and risk components for medication nonadherence inpatients with schizophrenia: a extensive overview of current literature. J Clin Psychiatry 2002, 63:892?09. 18. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC: Attitudes of schizophrenia outpatients toward psychiatric medicines: partnership to clinical variables and insight. J Clin Psychiatry 2004, 65(10):1372?. 19. Santone G, Rucci P, Muratori ML, Monaci A, Ciarafoni C, Borsetti G: Attitudes toward medication in inpatients with schizophrenia: a cluster analytic method. Psychiatry Res 2008, 158(three):324?4. 20. Schennach-Wolff R, Jager M, Seemuller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkotter J, Heuser I, Maier W, Lemke MR, Ruther E, Klingberg S, Gastpar M, Moller HJ, Riedel M: Attitude towards adherence in sufferers with schizophrenia at discharge. J Psychiatr Res 2009, 43(16):1294?01. 21. Adelufosi AO, Adebowale TO, Abayomi O, Mosanya JT: Medication adherence and quality of life among Nigerian outpatients with schizophrenia. Gen Hosp Psychiatry 2012, 34:72?. 22. Awad AG, Voruganti LN: New antipsychotics, compliance, quality of life, and subjective tolerability ?are sufferers greater off? Can J Psychiatry 2004, 49:297. 23. Morken G, Widen JH, Grawe RW: Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia.1240587-95-4 Order BMC Psychiatry 2008, eight:32?.5-Amino-6-methylnicotinonitrile manufacturer 24. Citrome L: Iloperidone, asenapine, and lurasidone: a short overview of 3 new second-generation antipsychotics. Postgraduate Medicine 2011, 123:153?62. 25. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A: Effectiveness of lurasidone in schizophrenia or schizoaffective disorder patients switched from other antipsychotics: a randomized, six-week, open-label study. J Clin Psychiatry 2013, 74(two):170?. 26. Buckley PF: Receptor-binding profiles of antipsychotics: clinical approaches when switching among agents. J Clin Psychiatry 2007, 68(six):5?. 27. Citrome L, Nasrallah HA: On-label around the table: what the package insert informs us concerning the tolerability profile of oral atypical antipsychotics, and what it does not.PMID:33559111 Specialist Opin Pharmacother 2012, 13(11):1599?613. 28. Voruganti L, Awad G: Personal evaluation of transitions in therapy (PETIT) a scale to measure subjective elements of antipsychotic drug therapy in schizophrenia. Schizophren Res 2002, 56:37?six. 29. Ware JE, Kosinski M, Keller SD: A 12-item short-form well being survey: building of scales and preliminary tests of reliability and validity. Health-related Care 1996, 34(3):220?33. 30. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, Conley RR: The cost of relapse as well as the predictors of relapse within the therapy of schizophrenia. BMC Psychiatry 2010, 10:two?. 31. Stahl SM: From antipsychotic agents. In Antipsychotics and Mood Stabilizers: Stahl’s Vital Psychopharmacology. 3rd edition. New York: Cambridge University Press; 2008:185?86. 32. Awad AG: Subjective tolerability of antipsychotic medications and also the emerging science of subjective tolerability disorders. Specialist R.